Evidence map›Paper›PMID 27798213›Full record

ArticleThe Journal of antimicrobial chemotherapy2017

Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.

Teclegiorgis Gebremariam, Nathan P Wiederhold, Abdullah Alqarihi, Priya Uppuluri, Nkechi Azie, John E Edwards, Ashraf S Ibrahim

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 51 citations in OpenAlex.

  1. Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Trial
  2. Article
  3. Review
  4. Review
  5. ISCCM Position Statement on the Management of Invasive Fungal Infections in the Intensive Care Unit.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Isavuconazole-Animal Data and Clinical Data.Journal of fungi (Basel, Switzerland) · 2020
    Review
  15. Article
  16. Article
  17. Animal Models to Study Mucormycosis.Journal of fungi (Basel, Switzerland) · 2019
    Review
  18. Article
  19. Review
  20. Therapy of Mucormycosis.Journal of fungi (Basel, Switzerland) · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Teclegiorgis GebremariamDivision of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, CA, USA.
Nathan P WiederholdUniversity of Texas Health Sciences at San Antonio, San Antonio, TX, USA.
Abdullah AlqarihiDivision of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, CA, USA.
Priya UppuluriDivision of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, CA, USA.
Nkechi AzieAstellas Pharma, Northbrook, IL, USA.
John E EdwardsDivision of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, CA, USA.
Ashraf S IbrahimDivision of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, CA, USA ibrahim@labiomed.org.
UCLA Medical Center · USAstellas Pharma (United States) · USThe University of Texas at San Antonio · USUniversity of California, Los Angeles · US

Funding

Novel Toxins and Receptors in Mucormycosis Pathogenesis and TreatmentR01AI063503 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2006 to 2025
$7.3M
NIAID NIH HHS R01 AI063503
6 · The paper itself

Abstract

objectivesPreviously we demonstrated the benefit of isavuconazole in treating murine mucormycosis due to Rhizopus. We wanted to determine the efficacy of isavuconazole in treating murine mucormycosis caused by Mucor, the second most common cause of the disease. Furthermore, because we previously determined that Rhizopus possesses the target enzyme for echinocandins and micafungin has activity against murine mucormycosis, we compared the activity of combination therapy (isavuconazole + micafungin) with placebo, either drug alone or standard therapy of liposomal amphotericin B (LAmB) in treating pulmonary murine mucormycosis caused by Rhizopus delemar.

methodsIn vitro susceptibility to isavuconazole of Mucorales was evaluated using the CLSI M38-A2 method. Immunosuppressed mice were intratracheally infected with either Mucor circinelloides or R. delemar. Treatment with isavuconazole (orally), micafungin (intraperitoneally), a combination of both or LAmB (intravenously) was compared, with survival and tissue fungal burden serving as primary and secondary endpoints, respectively.

resultsIsavuconazole was as effective as LAmB in prolonging survival of mice infected with M. circinelloides. Against R. delemar-induced mucormycosis, all monotherapy treatments significantly improved survival of mice versus placebo without showing superiority over one another. However, LAmB was superior in lowering fungal burden in target organs. Although combination therapy of isavuconazole + micafungin did not enhance survival of mice over monotherapy, antagonism was not detected between the two drugs.

conclusionIsavuconazole is effective in treating pulmonary murine mucormycosis due to Mucor. In addition, combination therapy of isavuconazole + micafungin does not demonstrate synergy and it is not antagonistic against Rhizopus-induced mucormycosis.

Indexed as

AnimalsAntifungal AgentsDrug Therapy, CombinationEchinocandinsLipopeptidesLungMaleMicafunginMiceMicrobial Sensitivity TestsMucorMucormycosisNitrilesPyridinesRhizopusTriazolesAntifungal AgentsEchinocandinsisavuconazoleLipopeptidesMicafunginNitrilesPyridinesTriazoles

Identifiers

PMID27798213
PMCPMC6289498
OpenAlexW2532880897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.